Provided by Tiger Trade Technology Pte. Ltd.

4D Molecular Therapeutics

13.67
-0.1700-1.23%
Post-market: 13.670.00000.00%19:30 EDT
Volume:1.04M
Turnover:14.27M
Market Cap:755.19M
PE:-4.96
High:14.14
Open:14.12
Low:13.60
Close:13.84
52wk High:16.93
52wk Low:6.96
Shares:55.24M
Float Shares:42.02M
Volume Ratio:0.92
T/O Rate:2.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.7580
EPS(LYR):-2.4200
ROE:-43.25%
ROA:-25.09%
PB:1.85
PE(LYR):-5.65

Loading ...

Press Release: 4DMT Announces New Employment Inducement Grants

Dow Jones
·
Jul 18

4D Molecular Therapeutics CEO David Kirn Sells USD 739,829 in Common Shares

Reuters
·
Jul 15

4D Molecular Therapeutics Chief Legal Officer Scott Bizily Disposes of 6,566 Common Shares Valued at $91,924

Reuters
·
Jul 03

4D Molecular Therapeutics to Present 2-year PRISM Phase 2b Data for 4d-150 Gene Therapy in Neovascular AMD at ASRS 2026

Reuters
·
Jul 01

Morgan Stanley Keeps Their Hold Rating on 4D Molecular Therapeutics (FDMT)

TIPRANKS
·
Jun 30

4D Molecular Therapeutics Buy Rating Reaffirmed on 4D-150 Pivotal Trial Momentum; Price Target Maintained at $36

TIPRANKS
·
Jun 30

4D Molecular Therapeutics Shares Rise After New Credit Facility

Dow Jones
·
Jun 29

4D Molecular Therapeutics Secures $200 Million Loan Facility

TIPRANKS
·
Jun 29

4D Molecular completes enrollment in 4FRONT-2 trial

TIPRANKS
·
Jun 29

4D Molecular Therapeutics Completes Enrollment for Phase 3 4d-150 Wet AMD Trial 4front-2

Reuters
·
Jun 29

4D Molecular Therapeutics - 4front-2 Over-enrolled with Anticipated N>500; Final Randomization Expected in Q3 2026

THOMSON REUTERS
·
Jun 29

4D Molecular Therapeutics - 4front-2 52-week Topline Data Expected in H2 2027

THOMSON REUTERS
·
Jun 29

4dmt Completes Enrollment for 4front-2 Global Phase 3 Clinical Trial of 4d-150 in Wet Amd

THOMSON REUTERS
·
Jun 29

4dmt Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

THOMSON REUTERS
·
Jun 29

Press Release: 4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

Dow Jones
·
Jun 29

Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of DR. Dean Baker

THOMSON REUTERS
·
Jun 26

4D Molecular Therapeutics Chief Legal Officer Scott Bizily Disposes of USD 117,720 in Common Shares

Reuters
·
Jun 26

4D Molecular Therapeutics CEO David Kirn disposes of 114,746 common shares worth $1.2 million

Reuters
·
Jun 24

4D Molecular Therapeutics Stockholders Back Directors and Governance

TIPRANKS
·
Jun 23

4D Molecular Therapeutics shareholders elect Class III directors at annual meeting

Reuters
·
Jun 23